好色先生

好色先生

Explore the latest content from across our publications
Join The AAN

Log In

Forgot Password?
Create New Account

Loading... please wait

Abstract Details

Impact of eptinezumab on work productivity beyond reductions in monthly migraine days: Post hoc analysis of the DELIVER trial
Headache
P13 - Poster Session 13 (8:00 AM-9:00 AM)
2-012

To identify drivers of work productivity improvement in patients with 2-4 prior preventive treatment failures receiving eptinezumab for migraine prevention.

A double-blinded, randomized, controlled trial (DELIVER; NCT04418765) showed that patients treated with intravenous eptinezumab infusions (up to 2 doses) over 24 weeks reported a larger improvement in absenteeism and presenteeism on the migraine-related Work Productivity and Activity Impairment (WPAI:M) scale compared with patients receiving placebo. However, there is limited evidence on how eptinezumab improves work productivity levels.

WPAI:M absenteeism and presenteeism subscores (measured as % of work time) from DELIVER were converted into hours using 2020 average actual working hours/week in Canada (36.9 hours/week). Regression analysis explored the association between number of monthly migraine days (MMDs) and hours affected by absenteeism or presenteeism, with treatment arm as a covariate. Path analysis then identified specific factors of treatment efficacy that were mediators of improved absenteeism and presenteeism.

Eptinezumab-treated patients reported larger reductions in hours affected by absenteeism and presenteeism compared to baseline than patients receiving placebo (difference vs placebo: absenteeism, ?7.2 hours/month, P<0.001; presenteeism, ?21.2 hours/month, P<0.001). Independent of treatment, there was an association between MMDs and hours affected by presenteeism and absenteeism. Comparing patients with equivalent MMDs at baseline between the eptinezumab and placebo arms, eptinezumab-treated patients demonstrated, on average, lower presenteeism (76.9 hours; P<0.001) and absenteeism (17.3 hours; P<0.001) than did corresponding patients receiving placebo (76.3 and 19.0 hours, respectively). Less than 40% of presenteeism improvement can be explained by reduction in MMDs (P<0.001), while more than 50% was mainly explained by self-reported improvement in patient-identified most bothersome symptom. 

Work productivity increases substantially in eptinezumab-treated patients compared to baseline and placebo. Eptinezumab reduces lost work productivity more than placebo and occurs through reduction of both migraine frequency and intensity of migraine symptoms.

 
Authors/Disclosures
Piero Barbanti, MD
PRESENTER 		Dr. Barbanti has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Abbvie. Dr. Barbanti has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Eli-Lilly. Dr. Barbanti has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for TEVA. Dr. Barbanti has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Fondazione Ricerca e Salute. Dr. Barbanti has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Lundbeck. Dr. Barbanti has received personal compensation in the range of $10,000-$49,999 for serving on a Speakers Bureau for Visufarma. Dr. Barbanti has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Assosalute. Dr. Barbanti has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Bayer. Dr. Barbanti has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Eli-Lilly. Dr. Barbanti has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Organon. Dr. Barbanti has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Novartis. Dr. Barbanti has received personal compensation in the range of $5,000-$9,999 for serving on a Speakers Bureau for TEVA. Dr. Barbanti has received publishing royalties from a publication relating to health care.
Susanne Awad (H. Lundbeck A/S) Susanne Awad has received personal compensation for serving as an employee of Lundbeck.
Stephane Regnier, PhD (Lundbeck) Mr. Regnier has received personal compensation for serving as an employee of Lundbeck. Mr. Regnier has received personal compensation for serving as an employee of Novartis. Mr. Regnier has stock in Novartis.
Xin Ying Lee (Lundbeck A/S) No disclosure on file
Peter Goadsby, MD, PhD, FRS (King Abdullah Univeristy of Science and Technology) Dr. Goadsby has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Abbvie. Dr. Goadsby has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Teva Pharmaceuticals. Dr. Goadsby has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Lundbeck. Dr. Goadsby has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Satsuma. Dr. Goadsby has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Pfizer. Dr. Goadsby has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Shiratronics. Dr. Goadsby has received personal compensation in the range of $500-$4,999 for serving as a Consultant for CoolTech LLC. Dr. Goadsby has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Linpharma. Dr. Goadsby has received personal compensation in the range of $500-$4,999 for serving as a Consultant for PureTech Health LLC. Dr. Goadsby has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Kallyope. Dr. Goadsby has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Seaport Therapeutics. Dr. Goadsby has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Dr Reddy's. Dr. Goadsby has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Orion Pharma. Dr. Goadsby has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Ipsen. Dr. Goadsby has received personal compensation in the range of $500-$4,999 for serving as an Editor, Associate Editor, or Editorial Advisory Board Member for Massachusetts Medical Society. The institution of Dr. Goadsby has received research support from NIHR. Dr. Goadsby has received publishing royalties from a publication relating to health care. Dr. Goadsby has received publishing royalties from a publication relating to health care. Dr. Goadsby has a non-compensated relationship as a Trustee with Migraine Trust that is relevant to AAN interests or activities. Dr. Goadsby has a non-compensated relationship as a Trustee with Organisation for Understanding Cluster Headache (UK) that is relevant to AAN interests or activities.